AL-LAD
N6-allyl LSD analog and lysergamide psychedelic acting primarily at 5-HT2A receptors, slightly less potent than LSD.
AL-LAD emerged on the new psychoactive substances market in 2013 and has been analytically characterized using NMR, GC-MS, and LC-MS methods. Behavioral studies in mice confirmed 5-HT2A-mediated head-twitch responses with potency slightly below LSD. In vitro metabolism studies of prodrug derivatives (1P-AL-LAD, 1cP-AL-LAD) confirmed conversion to AL-LAD as the primary metabolite. A published case report documented fatal ventricular dysrhythmia associated with AL-LAD use, though causality in isolation remains uncertain. Human pharmacokinetic data are extremely limited, and most potency comparisons are derived from rodent models, limiting direct translation to human dosing. No controlled clinical trials have been conducted.